Goldman Sachs
DCPH

Goldman Sachs’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History

Goldman Sachs’s Portfolio DCPH Stock Details DCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-15,000
Closed -$896K – 5584
2020
Q2 		$896K Sell
15,000
-10,000
-40% -$535K ﹤0.01% 4031
2020
Q1 		$1.03M Buy
25,000
+5,000
+25% +$278K ﹤0.01% 3733
2019
Q4 		$1.25M Hold
20,000
– – ﹤0.01% 3977
2019
Q3 		$679K Buy
+20,000
New +$592K ﹤0.01% 4281

Other funds holding DCPH

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Goldman Sachs's DCPH Position: Q2 2024 in Review

Goldman Sachs sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q2 2024, closing a stake of 1,962,841 shares — an estimated $30.9M sold.

Goldman Sachs first reported a position in DCPH in Q3 2017 and held it in 26 quarters. The position peaked at $69.7M in Q3 2022. 1 fund tracked by Wall St. Rank holds DCPH as of Q2 2024.

  • Goldman Sachs reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Goldman Sachs sold 1,962,841 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $30.9M.
  • Goldman Sachs first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q3 2017 and held it in 26 quarters.
  • Goldman Sachs's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $69.7M in Q3 2022.
  • 1 fund tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q2 2024.

Based on Goldman Sachs's 13F filing for Q2 2024, filed 13 Aug 2024.